Di Minno, G. and Ravasio, R. 2021. Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy. Global and Regional Health Technology Assessment. 8, 1 (Apr. 2021), 43–52. DOI:https://doi.org/10.33393/grhta.2021.2191.